Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.34 USD | -1.22% | -10.32% | -27.90% |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an enterprise value anticipated at 4.04 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.90% | 9.84B | A- | ||
-4.81% | 3.15B | C | ||
+31.37% | 2.99B | D+ | ||
-14.73% | 2.15B | - | B- | |
-14.39% | 1.8B | C+ | ||
+70.99% | 1.49B | B- | ||
+23.17% | 770M | C- | ||
-2.18% | 762M | C+ | ||
-20.41% | 575M | C- | ||
+3.18% | 308M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EXAS Stock
- Ratings Exact Sciences Corporation